EPKINLY Abbvie Pty Ltd

The sponsor proposes that EPKINLY (epcoritamab) be used on its own to treat adults with follicular lymphoma whose disease has come back or has not responded to treatment after two or more previous treatments. The sponsor also proposes that EPKINLY, when used together with lenalidomide and rituximab, be used to treat adults with follicular lymphoma whose disease has come back or has not responded to treatment. Follicular lymphoma is a B cell cancer, a type of white blood cell that is part of the immune system.